DXCM · XBRL financial data

Dexcom financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (DXCM's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	1,035*	921	1,004	994	1,114*	1,036	1,157	1,209	1,260*	1,192	1,308	1,345
Cost of goods and services sold	378*	359	378	400	458*	447	468	478	467*	442	478	480
Gross profit	657*	562	627	594	656*	589	689	731	793*	750	830	864
Research and development	136*	142	136	135	140*	145	148	158	148*	145	153	162
Selling, general and administrative	309*	319	333	306	327*	310	328	331	322*	350	359	376
Total operating expenses	440*	461	469	442	467*	455	476	489	470*	495	512	537
Other operating income (expense)	year only	—	(2)	(2)	(2)*	1	5	(1)	(2)*	(2)	(5)	(4)
Operating income (loss)	217*	101	158	152	189*	134	213	243	323*	255	318	327
Interest expense	5*	5	5	5	5*	5	5	5	4*	3	3	3
Other income (expense)	30*	31	30	25	22*	21	29	110	18*	14	(1)	8
Income tax expense (benefit)	(10)*	(14)	44	43	60*	49	61	69	73*	70	68	60
Net income (loss)	256*	146	144	135	152*	105	180	284	267*	200	249	275
Earnings per share, basic USD per share	0.67*	0.38	0.36	0.34	0.39*	0.27	0.46	0.73	0.69*	0.52	0.65	0.73
Earnings per share, diluted USD per share	0.60*	0.36	0.35	0.34	0.37*	0.27	0.45	0.70	0.67*	0.51	0.64	0.72
Weighted average shares, basic millions of shares	384*	390	399	394	391*	391	392	391	387*	385	382	375
Weighted average shares, diluted millions of shares	425*	417	417	410	407*	408	408	407	399*	394	390	384

Fiscal quarters (DXCM's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	566	851	939	621	606	905	1,159	1,836	918	1,118	1,105	961
Marketable securities	2,160	1,770	2,030	1,650	1,730	1,560	—	—	—	—	—	—
Marketable securities, non-current	—	276	156	217	248	237	—	—	—	—	—	—
Accounts receivable	974	979	945	1,002	1,006	1,155	1,349	1,110	1,216	1,089	1,258	1,186
Inventory	560	589	570	586	543	538	571	604	629	694	726	771
Prepaid and other current assets	168	156	212	182	174	159	181	184	189	134	156	141
Total current assets	4,426	4,621	4,848	4,263	4,301	4,554	5,030	5,220	4,033	4,332	4,087	3,916
Right-of-use asset	71	68	71	68	63	59	56	54	77	73	88	84
Goodwill	25	23	23	24	23	23	24	24	24	24	24	24
Total assets	6,265	6,482	6,799	6,354	6,485	6,752	7,327	7,500	6,340	6,633	6,455	6,239
Total current liabilities	1,556	1,594	1,722	1,735	2,932	3,037	3,309	3,336	2,143	2,224	2,358	2,253
Lease liability, non-current	80	76	77	71	65	60	55	51	73	69	83	78
Total liabilities	4,196	4,235	4,365	4,375	4,382	4,485	4,754	4,774	3,594	3,676	3,834	3,703
Retained earnings	1,021	1,168	1,311	1,446	1,598	1,703	1,883	2,167	2,434	2,633	2,883	3,158
Total stockholders' equity	2,069	2,247	2,434	1,979	2,103	2,267	2,573	2,726	2,746	2,957	2,621	2,535
Total liabilities and equity	6,265	6,482	6,799	6,354	6,485	6,752	7,327	7,500	6,340	6,633	6,455	6,239
Common shares outstanding (cover page) millions of shares	386	398	401	391	391	392	392	390	385	386	377	373

Fiscal quarters (DXCM's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	256*	146	144	135	152*	105	180	284	267*	200	249	275
Stock-based compensation	37*	39	45*	43*	43*	34	45*	45*	35*	43	39*	37*
Depreciation and amortization	53*	53	52	55	58*	60	63	64	65*	67	68	75*
Net cash from operating activities	134*	209	279*	200*	301*	184	303*	660*	294*	526	269*	326*
Purchases of property and equipment	53*	57	66*	111*	125*	87	94*	81*	102*	77	85*	53*
Net cash from investing activities	415*	75	(189)*	210*	(304)*	100	(64)*	193*	307*	(299)	330*	(77)*
Proceeds from issuing common stock	0*	13	0*	15*	0*	14	0*	14*	0*	13	0*	12*
Share repurchases	500*	—	—	750*	0*	—	—	187*	313*	—	—	400*
Net cash from financing activities	(632)*	5	(1)*	(737)*	(2)*	13	(2)*	(175)*	(1,522)*	(25)	(607)*	(392)*
Net change in cash	(77)*	285	88*	(318)*	(15)*	299	254*	677*	(918)*	199	(13)*	(144)*

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Dexcom	961	1,345	326*	373.0M	—	Q3 FY26 10-QSep 30, 2026
GE HealthCare Technologies	2,826	5,513	907*	452.1M	—	Q3 FY26 10-QSep 30, 2026
Resmed	1,011	1,415	422	140.7M	—	Q1 FY27 10-QSep 30, 2026
Edwards Lifesciences	2,907	1,741	652*	576.4M	—	Q2 FY26 10-QJun 30, 2026
STERIS	482	1,493	367	97.5M	—	Q1 FY27 10-QJun 30, 2026
Insulet	535	802	88*	69.4M	—	Q2 FY26 10-QJun 30, 2026
MiniMed Group	207	843	(49)	281.3M	2.3 quarters	Q1 FY27 10-QJul 31, 2026
Zimmer Biomet Holdings	410	2,177	448*	190.7M	—	Q2 FY26 10-QJun 30, 2026
Becton Dickinson	708	4,983	not reported	272.4M	—	Q3 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.